Shots:

• JAMP to get exclusive commercialization right for Alvotech’s five biosimilar therapies- having the market value of ~2B annually in Canada
• The collaboration allows JAMP to expand its generic portfolio- expected to exceed 500 products by 2022 and now has six biosimilars in its pipeline leading to an improvement in patient access to the therapies
• The partnership advances Alvotech's fully integrated value chain from cell line development to commercial manufacturing and allows patients to utilize biosimilars as well as the JAMP care patient support program in Canada

Click here ­to­ read full press release/ article | Ref: Newswire Canada | Image: Hans India